ReviewFEMS yeast research2026
Conserved and rewired MAPK networks in human fungal pathogens.
Review in FEMS yeast research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Mitogen-activated protein kinase (MAPK) cascades are among the most ancient and evolutionarily conserved signalling modules in eukaryotes, translating extracellular cues into adaptive transcriptional and metabolic outputs through a hierarchical three-tier kinase architecture. In yeasts, these pathways control osmotic and oxidative stress adaptation, mating, morphogenesis, and cell wall remodelling, while in fungal pathogens they have been adapted to support virulence-factor production, host adaptation, and antifungal tolerance. Here, we summarise the current understanding of MAPK signalling in the budding model yeast Saccharomyces cerevisiae, which serves throughout as a reference template, and in four human-pathogenic fungi that span the fungal kingdom-the ascomycetous yeast Candida albicans, the emerging multidrug-resistant pathogen Candidozyma (formerly Candida) auris, the filamentous mould Aspergillus fumigatus, and the basidiomycetous yeast Cryptococcus neoformans-emphasising how a conserved kinase framework has been functionally diversified to meet species-specific demands. We focus on the MAPK signalling system of C. neoformans, which is characterised by five MAPK homologues arising from paralogue retention and pervasive pathway crosstalk. We further discuss how recent systematic genetic dissection is prompting a reassessment of MAPK redundancy and network plasticity. Finally, we consider how the divergence between fungal and host MAPK signalling defines new conceptual and therapeutic directions in medical mycology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.